BACKGROUND Direct-acting antiviral agents(DAAs)are extremely effective in eradicating hepatitis C virus(HCV)in chronically infected patients.However,the protective role of the sustained virologic response(SVR)achieved...
Globally, 69.6 million individuals were infected with hepatitis C virus (HCV) infection in 2016. Of the six major HCV genotypes (GT), the most predominant one is GT1, worldwide. The prevalence of HCV in Central Asia, ...
Supported by Pooyesh Darou which is the local manufacturer of pegylated interferon alpha-2a in Iran(Pegaferon)
AIM: To evaluate the efficacy of pegylated interferon in Iranian chronic hepatitis C patients in relation to interferon-λ(IFNL) polymorphisms. METHODS: This study enrolled patients with chronic hepatitis C referred t...
AIM: To investigate the reduction in hepatitis B virus(HBV) covalently closed-circular DNA(ccc DNA) with entecavir(ETV) or lamivudine(LAM). METHODS: This analysis included patients who had participated in the randomiz...
Supported by Grants from the National Key Basic Research Program of China, No. 2009CB522507, No. 2012CB519005;Beijing Nova Program of China, No. Z12110702512071
Combination therapy with peginterferon (pegIFN)-α and ribavirin (RBV) has been the standard of care (SOC) for chronic hepatitis C. Unfortunately, not all patients can achieve a sustained virologic response (SVR) with...
The Natural Science Foundation of Yunnan Province, No.200300172;Hospital Science Foundation of The First People’s Hospital of Yunnan Province (2004)
AIM: To determine whether HBV with the same characteristics causes dissimilar mutations in different hosts. METHODS: Full-length HBV genome was amplified and linked with pMD T18 vector. Positive clones were selected b...
A grant from the Nanotechnology committee of the Ministry of Science, Research and Technology, Iran, No. 31.1895 on 05.03.2004 to Majid Sadeghizadeh
AIM: To characterize the clinical, serologic and virologic features of hepatitis B virus (HBV) infection in Iranian patients with different stages of liver disease.METHODS: Sixty two patients comprising of 12 inac...
Supported by the research grant of the Chungbuk National University in 2004
AIM: To identify the factors associated with virologic breakthrough and to select a subgroup of patients who respond well to lamivudine without developing virologic breakthrough (VBT). METHODS: Of 79 patients who had ...
AIM, To determine the prevalence of hepatitis B in Nahavand and evaluate the HBsAg positive prevalence in families with a member who was confirmed to have HBV infection. METHODS: This study was performed in two phase...
Supported by the Chang Gung Memorial Hospital Medical Research Program CMRPG-2044 and CMRP-800-VI
AIM: To assess the efficacy of ribavirin monotherapy in patients with biochemical relapse after combination therapy.METHODS: Twenty-four weeks of ribavirin monotherapy was given to biochemical relapsers of end treatme...